Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Next-generation proteasome inhibitor approved in multiple myeloma.

Literature DB >> 23138275

Next-generation proteasome inhibitor approved in multiple myeloma.

Alla Katsnelson.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2012 PMID： 23138275 DOI： 10.1038/nbt1112-1011

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

4 in total

1. The Multiple Myeloma Research Foundation's evolving focus on drug R&D.

Authors: Kathy Giusti
Journal: Nat Biotechnol Date: 2012-07-10 Impact factor: 54.908

2. New twists on proteasome inhibitors.

Authors: Jim Kling
Journal: Nat Biotechnol Date: 2010-12 Impact factor: 54.908

3. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors: David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal: Blood Date: 2012-07-25 Impact factor: 22.113

4. Initial genome sequencing and analysis of multiple myeloma.

Authors: Michael A Chapman; Michael S Lawrence; Jonathan J Keats; Kristian Cibulskis; Carrie Sougnez; Anna C Schinzel; Christina L Harview; Jean-Philippe Brunet; Gregory J Ahmann; Mazhar Adli; Kenneth C Anderson; Kristin G Ardlie; Daniel Auclair; Angela Baker; P Leif Bergsagel; Bradley E Bernstein; Yotam Drier; Rafael Fonseca; Stacey B Gabriel; Craig C Hofmeister; Sundar Jagannath; Andrzej J Jakubowiak; Amrita Krishnan; Joan Levy; Ted Liefeld; Sagar Lonial; Scott Mahan; Bunmi Mfuko; Stefano Monti; Louise M Perkins; Robb Onofrio; Trevor J Pugh; S Vincent Rajkumar; Alex H Ramos; David S Siegel; Andrey Sivachenko; A Keith Stewart; Suzanne Trudel; Ravi Vij; Douglas Voet; Wendy Winckler; Todd Zimmerman; John Carpten; Jeff Trent; William C Hahn; Levi A Garraway; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub
Journal: Nature Date: 2011-03-24 Impact factor: 49.962

4 in total

7 in total

1. Amgen swallows Onyx whole.

Authors: Malini Guha
Journal: Nat Biotechnol Date: 2013-10 Impact factor: 54.908

2. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.

Authors: Koichi Okamoto; Aziz Zaanan; Hisato Kawakami; Shengbing Huang; Frank A Sinicrope
Journal: Mol Cancer Res Date: 2014-12-29 Impact factor: 5.852

7. Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models.

Authors: L J Crawford; E T Chan; M Aujay; T L Holyoake; J V Melo; H G Jorgensen; S Suresh; B Walker; A E Irvine
Journal: Oncogenesis Date: 2014-03-03 Impact factor: 7.485

7 in total

Next-generation proteasome inhibitor approved in multiple myeloma.

1. The Multiple Myeloma Research Foundation's evolving focus on drug R&D.

2. New twists on proteasome inhibitors.

3. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

4. Initial genome sequencing and analysis of multiple myeloma.

1. Amgen swallows Onyx whole.

2. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.

Review 3. Ubiquitin and Ubiquitin-like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases.

4. A quantitative assay to monitor HSV-1 ICP0 ubiquitin ligase activity in vitro.

Review 5. Proteasome and Organs Ischemia-Reperfusion Injury.

6. Cardiovascular-specific mortality among multiple myeloma patients: a population-based study.

7. Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models.